Olema Oncology
The Senior Director, Biostatistics will lead the statistical strategy and execution for a pivotal Phase 3 clinical trial and associated NDA/ISS/ISE activities, reporting to the VP of Biostatistics. The role requires partnering cross-functionally to support trial planning, execution, and analysis while ensuring regulatory alignment and scientific rigor. This position is based in San Francisco, CA or Cambridge, MA and involves minimal travel (~10%).
Headquarters
San Francisco, California, United States
Company Size
51-200 employees
Founded
2007
Olema Oncology is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing novel targeted therapies for metastatic breast cancer and beyond. The company leverages its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance to advance its pipeline, including Phase 3 breast cancer trials and a KAT6 inhibitor program being evaluated in solid tumors and prostate cancer. Founded in 2006 and headquartered in San Francisco, California, Olema trades on Nasdaq under the ticker OLMA.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Olema Oncology.
Olema Oncology didn’t post a salary, so this is our estimate from similar listings.
Olema Oncology to Present at the TD Cowen 46th Annual Health Care Conference
3 weeks ago